Putting the freeze on biologics

Published: 18-Apr-2017

As more biologics and biosimilars come onto the market, they offer new treatment options for many cancers and autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, Crohn’s disease and psoriasis

You need to be a subscriber to read this article.
Click here to find out more.

However, these cutting-edge therapies are often moisture- and temperature-sensitive, presenting new packaging and containment challenges.

To ensure optimised storage and moisture protection for their injectable drug products, biopharmaceutical companies are increasingly turning to the process of lyophilisation for biologics and other drugs that are sensitive in liquid form or sensitive to their environment.

Lyophilisation is considered to be an ideal process for injectable drug products that may have a limited shelf-life in solution. Some drug formulations are unstable in aqueous solutions; the active ingredient can interact with, and degrade quickly in, water.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like